JP2019523651A5 - - Google Patents

Download PDF

Info

Publication number
JP2019523651A5
JP2019523651A5 JP2019505127A JP2019505127A JP2019523651A5 JP 2019523651 A5 JP2019523651 A5 JP 2019523651A5 JP 2019505127 A JP2019505127 A JP 2019505127A JP 2019505127 A JP2019505127 A JP 2019505127A JP 2019523651 A5 JP2019523651 A5 JP 2019523651A5
Authority
JP
Japan
Prior art keywords
antibody
antigen
binding fragment
composition
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019505127A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019523651A (ja
JP7323102B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/027154 external-priority patent/WO2017180713A1/en
Publication of JP2019523651A publication Critical patent/JP2019523651A/ja
Publication of JP2019523651A5 publication Critical patent/JP2019523651A5/ja
Application granted granted Critical
Publication of JP7323102B2 publication Critical patent/JP7323102B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019505127A 2016-04-13 2017-04-12 抗psma抗体およびその使用 Active JP7323102B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662321975P 2016-04-13 2016-04-13
US62/321,975 2016-04-13
PCT/US2017/027154 WO2017180713A1 (en) 2016-04-13 2017-04-12 Anti-psma antibodies and use thereof

Publications (3)

Publication Number Publication Date
JP2019523651A JP2019523651A (ja) 2019-08-29
JP2019523651A5 true JP2019523651A5 (enExample) 2020-05-21
JP7323102B2 JP7323102B2 (ja) 2023-08-08

Family

ID=60042213

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019505127A Active JP7323102B2 (ja) 2016-04-13 2017-04-12 抗psma抗体およびその使用

Country Status (10)

Country Link
US (1) US11414497B2 (enExample)
EP (1) EP3442567B1 (enExample)
JP (1) JP7323102B2 (enExample)
KR (1) KR102466763B1 (enExample)
CN (1) CN109641037B (enExample)
AU (1) AU2017250191A1 (enExample)
BR (1) BR112018070948A2 (enExample)
CA (1) CA3056374A1 (enExample)
RU (1) RU2018137110A (enExample)
WO (1) WO2017180713A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112469440B (zh) * 2018-06-18 2024-09-06 优瑞科生物技术公司 靶向前列腺特异性膜抗原(psma)的构建体和其用途
CN109627340B (zh) * 2018-12-05 2021-02-12 上海交通大学 Cd3和prlr双特异性抗体及其构建与应用
US10913770B2 (en) * 2019-05-14 2021-02-09 Vision Global Holdings Limited Mertansine polypeptide conjugates
GB201919019D0 (en) 2019-12-20 2020-02-05 Autolus Ltd Antigen-binding domain
CN110922486B (zh) * 2020-02-18 2020-05-22 和铂医药(上海)有限责任公司 一种分离的结合抗原psma的蛋白及其用途
TW202132353A (zh) * 2020-02-18 2021-09-01 大陸商和鉑醫藥(上海)有限責任公司 一種分離的結合抗原psma的蛋白及其用途
CN116323667A (zh) 2020-07-08 2023-06-23 拉法医疗股份有限公司 结合PSMA和γ-δT细胞受体的抗体
JP2024500189A (ja) 2020-12-21 2024-01-04 アロジーン セラピューティクス,インコーポレイテッド プロテアーゼ活性化cd45ゲートcar
MX2023008809A (es) 2021-01-29 2023-08-04 Allogene Therapeutics Inc ATENUACIÓN O INACTIVACIÓN DE UNO O MÁS DE TAP2, NLRC5, ß2M, TRAC, RFX5, RFXAP Y RFXANK PARA MITIGAR EL RECONOCIMIENTO DE CÉLULAS T DE PRODUCTOS CELULARES ALOGÉNICOS.
CN114306277B (zh) * 2021-11-02 2023-08-04 中国人民解放军空军军医大学 一种靶向psma的巨噬细胞膜包裹的仿生纳米药物载体及应用
KR20240164784A (ko) * 2022-03-30 2024-11-20 시 안 오리맵 바이오테크놀로지 컴퍼니 리미티드 항-psma 항체, 이의 변이체 및 이의 용도
JP7225458B1 (ja) 2022-05-10 2023-02-20 株式会社エクサウィザーズ 情報処理方法、コンピュータプログラム及び情報処理装置
US20240042030A1 (en) 2022-07-29 2024-02-08 Allogene Therapeutics, Inc. Engineered cells with reduced gene expression to mitigate immune cell recognition
KR102923942B1 (ko) * 2022-11-10 2026-02-06 (주)네오크레마 Il-22를 포함하는 융합 단백질 및 이의 용도
TW202442689A (zh) 2023-03-03 2024-11-01 美商亞森諾生物科學公司 靶向psma及ca9之系統
CN116271081A (zh) * 2023-04-04 2023-06-23 上海愿智生物技术有限公司 一种抗体偶联药物yc1605及其药物组合物和应用
KR20260105764A (ko) 2023-10-30 2026-07-07 알로젠 테라퓨틱스 인코포레이티드 조작된 세포
WO2025183244A1 (ko) * 2024-02-29 2025-09-04 주식회사 피비앱셀 Psma에 대한 항체 및 그의 용도

Family Cites Families (143)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4036945A (en) 1976-05-03 1977-07-19 The Massachusetts General Hospital Composition and method for determining the size and location of myocardial infarcts
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
EP0028683A1 (en) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
NO812612L (no) 1980-08-06 1982-02-08 Ferring Pharma Ltd Enzym-inhibitorer.
WO1982001188A1 (en) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
GB2116183B (en) 1982-03-03 1985-06-05 Genentech Inc Human antithrombin iii dna sequences therefore expression vehicles and cloning vectors containing such sequences and cell cultures transformed thereby a process for expressing human antithrombin iii and pharmaceutical compositions comprising it
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
CH668554A5 (de) 1984-04-09 1989-01-13 Sandoz Ag Liposomen welche polypeptide mit interleukin-2-aktivitaet enthalten sowie verfahren zu ihrer herstellung.
US4970198A (en) 1985-10-17 1990-11-13 American Cyanamid Company Antitumor antibiotics (LL-E33288 complex)
US4975282A (en) 1985-06-26 1990-12-04 The Liposome Company, Inc. Multilamellar liposomes having improved trapping efficiencies
ATE68968T1 (de) 1985-11-22 1991-11-15 Takeda Chemical Industries Ltd Liposomzusammensetzung.
US5079233A (en) 1987-01-30 1992-01-07 American Cyanamid Company N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same
JP2666345B2 (ja) 1987-04-16 1997-10-22 武田薬品工業株式会社 リポソーム製剤およびその製造法
US5273876A (en) 1987-06-26 1993-12-28 Syntro Corporation Recombinant human cytomegalovirus containing foreign gene
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
US5053394A (en) 1988-09-21 1991-10-01 American Cyanamid Company Targeted forms of methyltrithio antitumor agents
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
CN1033030C (zh) 1988-06-24 1996-10-16 唐化学原料公司 大环双官能螯合剂及其配合物和抗体共轭物的制备方法
US5756065A (en) 1988-06-24 1998-05-26 The Dow Chemical Company Macrocyclic tetraazacyclododecane conjugates and their use as diagnostic and therapeutic agents
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2045129A1 (en) 1989-02-01 1990-08-02 Alfred I. Geller Herpes simplex virus type i expression vector
US5665577A (en) 1989-02-06 1997-09-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
EP0549723A1 (en) 1990-09-21 1993-07-07 Chiron Corporation Packaging cells
ATE188740T1 (de) 1991-02-19 2000-01-15 Univ California Viruspartikel mit veraendertem wirtspektrum
GB9105383D0 (en) 1991-03-14 1991-05-01 Immunology Ltd An immunotherapeutic for cervical cancer
AU3972893A (en) 1992-04-03 1993-11-08 Baylor College Of Medicine Gene therapy using the intestine
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
ATE139900T1 (de) 1992-11-13 1996-07-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
AU6014094A (en) 1992-12-02 1994-06-22 Baylor College Of Medicine Episomal vectors for gene therapy
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
FR2702160B1 (fr) 1993-03-02 1995-06-02 Biovecteurs As Vecteurs particulaires synthétiques et procédé de préparation.
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
AU7353494A (en) 1993-11-12 1995-05-29 Case Western Reserve University Episomal expression vector for human gene therapy
US5928944A (en) 1994-02-04 1999-07-27 The United States Of America As Represented By The Department Of Health And Human Services Method of adenoviral-medicated cell transfection
US5731172A (en) 1994-03-09 1998-03-24 Sumitomo Pharmaceuticals Company, Ltd. Recombinant adenovirus and process for producing the same
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5604090A (en) 1994-06-06 1997-02-18 Fred Hutchinson Cancer Research Center Method for increasing transduction of cells by adeno-associated virus vectors
US5693508A (en) 1994-11-08 1997-12-02 Chang; Lung-Ji Retroviral expression vectors containing MoMLV/CMV-IE/HIV-TAR chimeric long terminal repeats
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
JP3770333B2 (ja) 1995-03-15 2006-04-26 大日本住友製薬株式会社 組換えdnaウイルスおよびその製造方法
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US6110456A (en) 1995-06-07 2000-08-29 Yale University Oral delivery or adeno-associated viral vectors
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5766905A (en) 1996-06-14 1998-06-16 Associated Universities Inc. Cytoplasmic bacteriophage display system
US6111090A (en) 1996-08-16 2000-08-29 Schering Corporation Mammalian cell surface antigens; related reagents
DK0920505T3 (da) 1996-08-16 2008-09-08 Schering Corp Pattedyrcelleoverfladeantigener og tilhörende reagenser
US5861397A (en) 1996-10-03 1999-01-19 Vical Incorporated Piperazine based cytofectins
US6096291A (en) 1996-12-27 2000-08-01 Biovector Therapeutics, S.A. Mucosal administration of substances to mammals
US20030148463A1 (en) * 1997-04-14 2003-08-07 Micromet Ag Novel method for the production of anti-human antigen receptors and uses thereof
US6054312A (en) 1997-08-29 2000-04-25 Selective Genetics, Inc. Receptor-mediated gene delivery using bacteriophage vectors
CA2308114A1 (en) 1997-10-21 1999-04-29 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins tr11, tr11sv1, and tr11sv2
JP2002502607A (ja) 1998-02-09 2002-01-29 ジェネンテク・インコーポレイテッド 新規な腫瘍壊死因子レセプター相同体及びそれをコードする核酸
ATE376837T1 (de) 1999-07-12 2007-11-15 Genentech Inc Stimulierung oder hemmung von angiogenese und herzvaskularisierung mit tumor nekrose faktor ligand/rezeptor homologen
ES2277846T3 (es) * 1999-07-29 2007-08-01 Medarex, Inc. Anticuerpos monoclonales humanos para antigeno prostatico especifico.
EP1235842A4 (en) 1999-10-15 2003-04-23 Univ Massachusetts Rna interference pathway genes as tools for targeted genetic interference
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
HK1052372A1 (zh) 2000-02-24 2003-09-11 Xcyte Therapies, Inc. 细胞的同步刺激和富集
WO2001096584A2 (en) 2000-06-12 2001-12-20 Akkadix Corporation Materials and methods for the control of nematodes
WO2002044209A2 (en) * 2000-11-28 2002-06-06 Zymogenetics, Inc. Cytonkine receptor zcytor19
ES2255616T3 (es) 2001-04-27 2006-07-01 Alexion Pharmaceuticals, Inc. Vectores fagemidos.
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US7666414B2 (en) 2001-06-01 2010-02-23 Cornell Research Foundation, Inc. Methods for treating prostate cancer using modified antibodies to prostate-specific membrane antigen
US7521053B2 (en) * 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US20050215472A1 (en) 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
WO2003034903A2 (en) 2001-10-23 2003-05-01 Psma Development Company, L.L.C. Psma antibodies and protein multimers
US7745140B2 (en) 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
EP1478648B1 (en) 2002-02-01 2014-04-30 ARIAD Pharmaceuticals, Inc. Phosphorus-containing compounds and uses thereof
EP1391213A1 (en) 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
AU2004244626A1 (en) 2003-05-23 2004-12-09 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services GITR ligand and GITR ligand-related molecules and antibodies and uses thereof
EP1660126A1 (en) 2003-07-11 2006-05-31 Schering Corporation Agonists or antagonists of the clucocorticoid-induced tumour necrosis factor receptor (gitr) or its ligand for the treatment of immune disorders, infections and cancer
ES2605443T3 (es) 2003-11-06 2017-03-14 Seattle Genetics, Inc. Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia
EP1692318A4 (en) 2003-12-02 2008-04-02 Genzyme Corp COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF LUNG CANCER
WO2005062977A2 (en) * 2003-12-23 2005-07-14 The Regents Of The University Of California Prostate cancer specific internalizing human antibodies
GB0409799D0 (en) 2004-04-30 2004-06-09 Isis Innovation Method of generating improved immune response
AU2005250408B2 (en) 2004-05-27 2010-09-23 The Trustees Of The University Of Pennsylvania Novel artificial antigen presenting cells and uses therefor
EP1765402A2 (en) 2004-06-04 2007-03-28 Duke University Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
CA2598454C (en) 2005-02-18 2013-04-09 Medarex, Inc. Monoclonal antibodies against prostate specific membrane antigen (psma) lacking in fucosyl residues
ES2386366T3 (es) 2005-02-18 2012-08-17 Medarex, Inc. Anticuerpo monoclonal humano contra el antígeno de membrana específico de la próstata (PSMA)
JP5238936B2 (ja) 2005-03-25 2013-07-17 ジーアイティーアール,インク. Gitr結合分子およびその使用
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
WO2007133822A1 (en) 2006-01-19 2007-11-22 Genzyme Corporation Gitr antibodies for the treatment of cancer
AU2007353412A1 (en) * 2006-11-21 2008-11-20 Fox Chase Cancer Center Anti-EGFR family antibodies, bispecific anti-EGFR family antibodies and methods of use thereof
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
PT2175884T (pt) 2007-07-12 2016-09-21 Gitr Inc Terapias de combinação empregando moléculas de ligação a gitr
PT2242773T (pt) 2008-02-11 2017-09-15 Cure Tech Ltd Anticorpos monoclonais para o tratamento de tumores
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
JP2011526794A (ja) 2008-07-02 2011-10-20 エマージェント プロダクト デベロップメント シアトル, エルエルシー TGF−βアンタゴニスト多重標的結合性分子
WO2010098788A2 (en) 2008-08-25 2010-09-02 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
EA201500417A1 (ru) 2008-08-25 2015-11-30 Эмплиммьюн, Инк. Композиции антагонистов pd-1 и способы применения
JPWO2010030002A1 (ja) 2008-09-12 2012-02-02 国立大学法人三重大学 外来性gitrリガンド発現細胞
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
WO2010089411A2 (en) 2009-02-09 2010-08-12 Universite De La Mediterranee Pd-1 antibodies and pd-l1 antibodies and uses thereof
IN2015DN02826A (enExample) 2009-09-03 2015-09-11 Merck Sharp & Dohme
WO2011053763A2 (en) * 2009-10-30 2011-05-05 Centocor Ortho Biotech Inc. Il-17a antagonists
GB0919054D0 (en) 2009-10-30 2009-12-16 Isis Innovation Treatment of obesity
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
US20130089554A1 (en) 2009-12-29 2013-04-11 Emergent Product Development Seattle, Llc RON Binding Constructs and Methods of Use Thereof
TWI653333B (zh) * 2010-04-01 2019-03-11 安進研究(慕尼黑)有限責任公司 跨物種專一性之PSMAxCD3雙專一性單鏈抗體
US8734774B2 (en) 2010-04-02 2014-05-27 University Of Rochester Protease activated cytokines
US20120213771A1 (en) * 2010-04-13 2012-08-23 Celldex Therapeutics Inc. Antibodies that bind human cd27 and uses thereof
AU2011295702A1 (en) * 2010-09-02 2013-04-04 Excelimmune, Inc. Staphylococcus aureus specific human recombinant polyclonal antibodies and uses thereof
US20130108641A1 (en) 2011-09-14 2013-05-02 Sanofi Anti-gitr antibodies
CA3285826A1 (en) 2012-02-22 2026-03-02 The Trustees Of The University Of Pennsylvania Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer
TR201900694T4 (tr) 2012-08-23 2019-02-21 Agensys Inc 158p1d7 proteinlerine bağlanan antikor ilaç konjugatları (adc).
CN104955839A (zh) * 2013-01-28 2015-09-30 株式会社伊贝克 对人偏肺病毒具有特异性的人抗体或其抗原结合性片段
FI126746B (en) * 2014-04-07 2017-05-15 Teknologian Tutkimuskeskus Vtt Oy Antibody to HT-2 Toxin-HT-2 Toxin Antibody Complex
JOP20160154B1 (ar) 2015-07-31 2021-08-17 Regeneron Pharma أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها

Similar Documents

Publication Publication Date Title
RU2018137110A (ru) Антитела против psma и их применение
RU2447084C2 (ru) Антитела к gdf8 и их применения
HRP20191341T1 (hr) Protutijela koja vežu ljudski cgrp receptor
JP7257971B6 (ja) 抗cd40抗体、その抗原結合フラグメント、およびその医学的使用
JP2013506428A5 (enExample)
RU2019121086A (ru) Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1)
JP2020514277A5 (enExample)
RU2016100892A (ru) Антитела против tweakr и их применение
WO2013188864A4 (en) Anti-cd22 anti-idiotypic antibodies and uses thereof
JP2021500916A5 (enExample)
JP2022533538A5 (enExample)
EA201391159A1 (ru) Hla-рестриктированные пептидоспецифические антигенсвязывающие белки
JP2019506412A5 (enExample)
JP2016505634A5 (enExample)
CN111393529B (zh) 与ox40l非竞争结合的抗ox40抗体
JP2018528776A5 (enExample)
RU2018102803A (ru) Мультивалентные и мультиспецифические гибридные белки, связывающиеся с dr5
JP2018522888A5 (enExample)
JP2020534012A5 (enExample)
JP2017521054A5 (enExample)
PH12022552520A1 (en) Antibodies binding siglec15 and uses thereof
CA3244652A1 (en) Anti-GPRC5D Antibodies and Their Use
JP2019505477A5 (enExample)
JP2024540148A5 (enExample)
JP2020513759A5 (enExample)